[go: up one dir, main page]

NO962812L - Procedure for the treatment of neurogenic inflammation - Google Patents

Procedure for the treatment of neurogenic inflammation

Info

Publication number
NO962812L
NO962812L NO962812A NO962812A NO962812L NO 962812 L NO962812 L NO 962812L NO 962812 A NO962812 A NO 962812A NO 962812 A NO962812 A NO 962812A NO 962812 L NO962812 L NO 962812L
Authority
NO
Norway
Prior art keywords
neurogenic inflammation
procedure
treatment
alkoxy
cgb
Prior art date
Application number
NO962812A
Other languages
Norwegian (no)
Other versions
NO962812D0 (en
Inventor
Knud Erik Andersen
Uffe Bang Olsen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO962812D0 publication Critical patent/NO962812D0/en
Publication of NO962812L publication Critical patent/NO962812L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Fremgangsmåte for behandling av neurogen inflammasjon hos et individ som trenger det, omfattende admini- strering av en effektiv mengde av en forbindelse med formel (I) \ .(CHjJnCGB. (D hvor R1 og R2 uavhengig av hverandre er hydrogen, halogen, trifluormetyl, Ct_6- alkyl eller C^-alkoksy; Y er >N-CH2-, >CH-CH2- eller >C=CH- når s er O, l eller 2, eller Y er >CH-CH=N- eller >C=N- når s er O, hvor bare det under- strekede atom deltar i ringsystemet; X er -O-; Z er -O-, -S-, -CH2-, -CH2- CH2-, -CH=CH-CH2-, -CH2-CH=CH-, -CH2CH2- CH2-, -CH=CH- eller -O-CH2-; R4 og R5 er hver hydrogen eller kan, når m er 2, til sammen være en binding; R6 er OH eller C^-alkoksy; p er O eller 1; qer O eller 1; ser O, l eller 2; rer 2, 3 eller 4; mer l eller 2; ner l når m er l, eller n er O når m er 2; eller et farmasøytisk akseptabelt salt derav, til individet.A method of treating neurogenic inflammation in an individual in need thereof, comprising administering an effective amount of a compound of formula (I) \ (CH 2 J CGB. (D C 1-6 alkyl or C 1-6 alkoxy; Y is> N-CH 2 -> CH-CH 2 - or> C = CH- when s is 0, 1 or 2, or Y is> CH-CH = N- or> C = N- when s is O, where only the underlined atom participates in the ring system; X is -O-; Z is -O-, -S-, -CH2-, -CH2- CH2-, -CH = CH- CH2-, -CH2 -CH = CH-, -CH2CH2- CH2-, -CH = CH- or -O-CH2-; R4 and R5 are each hydrogen or, when m is 2, may together form a bond; R6 is OH or C 1 -alkoxy; p is O or 1; is O or 1; is O, 1 or 2; is 2, 3 or 4; more 1 or 2; n is 1 when m is 1 or n is 0 when m is 2, or a pharmaceutically acceptable salt thereof, to the subject.

NO962812A 1994-01-04 1996-07-03 Procedure for the treatment of neurogenic inflammation NO962812L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK2094 1994-01-04
PCT/DK1995/000003 WO1995018615A1 (en) 1994-01-04 1995-01-03 A method of treating neurogenic inflammation

Publications (2)

Publication Number Publication Date
NO962812D0 NO962812D0 (en) 1996-07-03
NO962812L true NO962812L (en) 1996-09-04

Family

ID=8088844

Family Applications (1)

Application Number Title Priority Date Filing Date
NO962812A NO962812L (en) 1994-01-04 1996-07-03 Procedure for the treatment of neurogenic inflammation

Country Status (13)

Country Link
EP (1) EP0735872A1 (en)
JP (1) JPH09507849A (en)
CN (1) CN1142183A (en)
AU (1) AU1311195A (en)
BR (1) BR9506453A (en)
CA (1) CA2180239A1 (en)
CZ (1) CZ198396A3 (en)
FI (1) FI962750A7 (en)
HU (1) HUT76281A (en)
IL (1) IL112223A0 (en)
NO (1) NO962812L (en)
WO (1) WO1995018615A1 (en)
ZA (1) ZA9530B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997022342A1 (en) * 1995-12-15 1997-06-26 Novo Nordisk A/S Novel method
US7417040B2 (en) 2004-03-01 2008-08-26 Bristol-Myers Squibb Company Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2965639A (en) * 1960-12-20 New basically substituted azepine
FI864246A7 (en) * 1985-11-08 1987-05-09 Warner Lambert Co N-SUBSTITUERADE 3-PIPERIDINE- ELLER 3-PYRIDINE CARBOXYLSYROR SAMT DERAS DERIVATS.
DK93791D0 (en) * 1991-05-17 1991-05-17 Novo Nordisk As NEW HETEROCYCLIC CARBOXYLIC ACIDS

Also Published As

Publication number Publication date
CN1142183A (en) 1997-02-05
JPH09507849A (en) 1997-08-12
CZ198396A3 (en) 1997-01-15
BR9506453A (en) 1997-09-02
EP0735872A1 (en) 1996-10-09
HU9601826D0 (en) 1996-09-30
FI962750L (en) 1996-09-04
CA2180239A1 (en) 1995-07-13
FI962750A0 (en) 1996-07-04
ZA9530B (en) 1996-07-04
NO962812D0 (en) 1996-07-03
AU1311195A (en) 1995-08-01
FI962750A7 (en) 1996-09-04
HUT76281A (en) 1997-07-28
IL112223A0 (en) 1995-03-30
WO1995018615A1 (en) 1995-07-13

Similar Documents

Publication Publication Date Title
TW429250B (en) Novel heterocyclic derivatives and pharmaceutical use thereof
ES8707223A1 (en) Benzothiazole and benzothiophene derivatives.
HUP0002347A2 (en) Use of hydantoin, oxazole and pyrrole derivatives for the preparation of pharmaceutical compositions inflammatory disease treating
UA43391C2 (en) Method of cohesion inhibition and the method of inflammatory process inhibition and disrupted process of normal coagulation in patients with the disorders of the vascular endothelium
ATE218864T1 (en) USE OF PIPERIDINE DERIVATIVES IN THE TREATMENT OF SCHIZOPHRENIA
AU7578894A (en) Methods for inhibiting smooth muscle cell proliferation and restinosis
HUP9900926A2 (en) New 4-(oxyalkoxyphenyl)-3-oxy-piperidines for treating heart and kidney insufficiency
HUP9901652A2 (en) Use of piperidine-carboxylic acid derivatives for producing pharmaceutical compositions suitable for reducing blood glucose
ATE139233T1 (en) ANNELATED THIOPHENE DERIVATIVES, THEIR PREPARATION AND USE
MY112973A (en) Methods for inhibiting vascular smooth muscle cell migration
FI922345A0 (en) Process for the preparation of therapeutically useful 3-substituted pyrrolidine derivatives
DE3853459D1 (en) Treatment of glaucoma.
DK0771200T3 (en) Use of raloxifene and its analogues in the manufacture of a medicament for the treatment of viral diseases
MX9701360A (en) Methods of inhibiting demyelinating and dysmyelinating diseases.
NO954576D0 (en) AMPA antagonists and a method of treating them
FR2679555B1 (en) NEW DERIVATIVES OF UREAE, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS.
NO962812L (en) Procedure for the treatment of neurogenic inflammation
NO900697L (en) PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE ACETAMIDE DERIVATIVES.
HUP9701921A2 (en) Heterocyclic amino-methyl compounds, process for producing them, and pharmaceutical compositions containing them
NO945079D0 (en) Cyclopentadienylmagnesium bridges, process for their preparation, and their use for the preparation of metallocenes
NO984920L (en) Preparations comprising a nitron compound for use in the treatment of ocular inflammation
NO943567L (en) Bridged bis-arylcarbinol derivatives, preparations and methods of use
NO991581L (en) N- (benzothiazol-2-yl) piperidine-1-ethanamine derivatives, their preparation and use in therapeutic agents
FI895012A0 (en) CEILINGS INNEHAOLLANDE NITROXIALKYLAMINER MED AMIDFUNKTION SAMT FOERFARANDE FOER FRAMSTAELLNING AV NAEMNDA FOERENINGAR.
DK43384D0 (en) BICYCLOOCTAN DERIVATIVES, PROCEDURES FOR THEIR PREPARATION AND APPLICATION OF THEM